<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>12(9)</volume><submitter>Perez-Martinez L</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>As age increases, the risk of developing fragility also increases. Improving the knowledge of frailty could contribute to maintaining the functional ability of elderly people. Interleukin (IL)-10 homozygous knockout mice (IL-10&lt;sup>tm/tm&lt;/sup> [IL10KO]) constitute an excellent tool for the study of frailty. Because patients with frailty demonstrate an overexpression of CCR5, rapamycin (RAPA) and/or maraviroc (MVC), two molecules able to decrease CCR5 expression, were evaluated.&lt;h4>Results&lt;/h4>Muscle myostatin was reduced in all the therapeutic groups but the MVC group (p &lt;0.001 for RAPA and MVC-RAPA) and in serum samples (p &lt;0.01 for all the groups). Serum CK levels were also significantly lower in MVC and RAPA groups (p &lt;0.01 in both cases). Lower AST levels were observ</pubmed_abstract><journal>Aging</journal><pagination>8565-8582</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7244075</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Implications of maraviroc and/or rapamycin in a mouse model of fragility.</pubmed_title><pmcid>PMC7244075</pmcid><pubmed_authors>Carnero A</pubmed_authors><pubmed_authors>Munoz-Galvan S</pubmed_authors><pubmed_authors>Perez-Martinez L</pubmed_authors><pubmed_authors>Romero L</pubmed_authors><pubmed_authors>Rubio-Mediavilla S</pubmed_authors><pubmed_authors>Oteo JA</pubmed_authors><pubmed_authors>Verdugo-Sivianes EM</pubmed_authors><pubmed_authors>Blanco JR</pubmed_authors></additional><is_claimable>false</is_claimable><name>Implications of maraviroc and/or rapamycin in a mouse model of fragility.</name><description>&lt;h4>Background&lt;/h4>As age increases, the risk of developing fragility also increases. Improving the knowledge of frailty could contribute to maintaining the functional ability of elderly people. Interleukin (IL)-10 homozygous knockout mice (IL-10&lt;sup>tm/tm&lt;/sup> [IL10KO]) constitute an excellent tool for the study of frailty. Because patients with frailty demonstrate an overexpression of CCR5, rapamycin (RAPA) and/or maraviroc (MVC), two molecules able to decrease CCR5 expression, were evaluated.&lt;h4>Results&lt;/h4>Muscle myostatin was reduced in all the therapeutic groups but the MVC group (p &lt;0.001 for RAPA and MVC-RAPA) and in serum samples (p &lt;0.01 for all the groups). Serum CK levels were also significantly lower in MVC and RAPA groups (p &lt;0.01 in both cases). Lower AST levels were observ</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Apr</publication><modification>2025-04-18T14:36:01.65Z</modification><creation>2020-06-07T07:12:14Z</creation></dates><accession>S-EPMC7244075</accession><cross_references><pubmed>32353830</pubmed><doi>10.18632/aging.103167</doi></cross_references></HashMap>